Gerresheimer Shares Plunge Amid Deepening Crisis

The investment community is losing faith in Gerresheimer at an alarming rate. Following closely on the heels of a recent profit warning and disappointing quarterly figures, the pharmaceutical supplier’s stock has experienced another dramatic decline. This marks the second time this year that management has downgraded its annual forecast, triggering a widespread investor exodus. Market participants are now questioning whether this represents a potential turning point for the company or if the downward spiral has much further to go.

Mounting Pressures: Regulatory Scrutiny and Short Sellers Compound Troubles

Beyond its operational challenges, Gerresheimer faces additional headwinds. Germany’s financial regulator, BaFin, is currently examining the company for potential accounting irregularities, creating another layer of uncertainty. Simultaneously, speculative activity against the stock has intensified. With a short interest of 8.4 percent, Gerresheimer ranks among the most heavily shorted equities in the European market, reflecting deep-seated pessimism about its near-term prospects.

A Forecast Reversal: From Growth to Contraction

The company’s revised outlook for 2025 paints a starkly different picture from initial expectations, signaling a significant deterioration in performance:

• Organic Revenue Decline: Projected to be between -2% and -4%, a sharp reversal from the previously guided growth range of 0% to +2%.
• Adjusted EBITDA Margin: Now anticipated to be only 18.5% to 19%.
• Transformation Strategy: A new cost-reduction program has been unveiled as a critical component of the recovery plan.

The third-quarter results underscore this dramatic shift. An organic revenue decline of 1.2 percent and an EBITDA margin of just 18.8 percent suggest the company’s structural issues are more profound than previously anticipated.

Should investors sell immediately? Or is it worth buying Gerresheimer?

Structural Weaknesses Exposed

At the heart of Gerresheimer’s troubles is a persistent and unresolved issue: severely dampened demand within its cosmetics and oral liquids segments. This weakness appears structural in nature, unlikely to be resolved in the short term. While company leadership is pinning its hopes on planned production ramp-ups for drug-delivery systems in the fourth quarter, investors are skeptical whether this will be sufficient to halt the negative trend.

The stock’s performance tells its own story. Having shed over 18 percent of its value in a single week and plummeting a substantial 56 percent since the start of the year, Gerresheimer stands as one of the worst performers in the German equity market.

The critical question now is whether the newly announced transformation program—combining cost-cutting measures and the planned separation of the Moulded Glass division from 2026—can genuinely engineer a recovery. Alternatively, has the management’s credibility and ability to forecast been so severely damaged that a loss of investor confidence is irreversible? The upcoming quarterly report will serve as a crucial test.